STALLERGENES-GREER
18.5.2020 09:07:12 CEST | Business Wire | Press release
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products (SCIT), further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005223/en/
“Stallergenes Greer is committed to the disciplined execution of the company’s strategy and is well advanced on its transformation journey. Our robust fundamentals, investments in quality, and commitment to operational excellence continue to yield results as evidenced by the expansion of SCIT products, the widening of our portfolio and the solidifying of our leadership positions in various markets. We can be proud of our achievements and look ahead with confidence,” declares Michele Antonelli, Chief Executive Officer.
Acceleration of SCIT production
In April 2020, the French Agency for Medicines and Health (ANSM) lifted its injunction, which primarily impacted the production of subcutaneous products for the Europe and International region. SCIT production will fully resume in Antony, France, in the coming weeks, starting with skin prick tests (Alyostal® pricks) for diagnosis, and Alustal® for the treatment of patients with allergies. SCIT production in the US, where Stallergenes Greer continues to lead the market, has remained fully operational and was not part of the injunction.
With sustained investments in its global manufacturing capabilities, Stallergenes Greer operates state-of-the-art manufacturing and quality systems that meet the highest product quality standards.
Stallergenes Greer intends to further provide injectable forms with the resumption of Phostal®.
SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician.
Further broadening the allergen immunotherapy treatment portfolio
Stallergenes Greer remains determined to offer an extensive portfolio of treatment solutions tailored to each patient profile and to each market, including injectable therapies, sublingual therapies such as drops and tablets, venoms and diagnostics. From diagnosis to treatment, Stallergenes Greer’s portfolio is designed to ensure the consistency of its products in terms of active ingredients and high-quality standards. It allows physicians to choose the administration method which is best suited to each patient’s needs and lifestyle.
In 2019 alone, the company added 15 new Staloral® allergen references to its sublingual portfolio and will launch another 10 references in 2020.
Stallergenes Greer, also continued to enhance its tablet offering which already includes Oralair® for the treatment of grass pollen allergies and Actair® for the treatment of house dust mite allergies, which is distributed in selected countries of the Asia-Pacific region.
The company recently submitted a European marketing application authorisation for its house dust mite allergy immunotherapy tablet. The tablet is also under New Drug Submission review by Health Canada.
Stallergenes Greer is delivering on the disciplined execution of its strategy of providing people with allergies a broad range of personalised treatment options, which will make it both a company with a complete portfolio and a valued partner for patients and the medical community.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in MSI-High Solid Tumors10.11.2026 13:00:00 CET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System designed to identify patients with microsatellite high (MSI-H) solid tumors as a companion diagnostic designed for KEYTRUDA®, Merck’s (known as MSD outside the U.S. and Canada) anti-PD-1 therapy. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in solid tumor tissue. MSI status can be used to inform treatment decisions and support precision oncology strategies. “This approval reflects our dedication to providing meaningful diagnostic advances, developed to the highest quality and regulatory standards,” says Alok Sharma, Global Clinical Market Director at Promega. “Our test connects patients with the therapy most likely to help them, working alongside our pharmaceutical collaborators and the clinicians who use the result.” This approval was supported through a collaboration with Merck, which markets KEYTRUDA®. Together, the companies are working to a
Component Sense Celebrates 25 Years With Over 80 Million Electronic Components Saved From Landfill10.11.2026 13:00:00 CET | Press release
Global electronics redistribution company marks its anniversary by planting 2,500 trees Component Sense, a global company specialising in the redistribution of excess and obsolete electronic components, has now saved over 80 million components from landfill. The milestone coincides with its 25th anniversary this November, which it is marking by planting 2,500 trees with One Tree Planted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110298637/en/ Kenny McGee, CEO and Founder, Component Sense The company redistributes excess components from Tier 1 original equipment manufacturers (OEMs) and electronics manufacturing services (EMS) providers to a global network of buyers, helping manufacturers recoup value from inventory that would otherwise go to waste. Excess inventory is both a financial and an environmental burden for electronics manufacturers. With lead times still running long, shortages and surpluses exist side by s
Suzano Publishes First Report Aligned With Taskforce on Nature-related Financial Disclosures Recommendations10.11.2026 12:18:00 CET | Press release
Report offers insight on Suzano’s ecosystem health impacts, risks and opportunities, and reinforces its nature strategy Suzano, the world’s largest pulp producer, has published its first report aligned with the recommendations of the Taskforce on Nature-related Financial Disclosures (TNFD). The TNFD reporting framework helps organizations identify and assess how their dependencies and impacts may generate nature and biodiversity related risks and opportunities, and to disclose how they are integrated into the company’s governance, strategy, and corporate management. Initially focused on Suzano’s direct Brazilian operations, the report establishes methodological foundations, strengthens internal capabilities, and creates a pathway for the gradual expansion of nature-related assessments and disclosures over the coming years. The report also reinforces Suzano’s Nature Strategy, launched in November 2025. As part of its ongoing commitment to stronger management and greater transparency reg
Robbyant Releases LingBot-Touch to Bring General-Purpose Touch Perception to Robots10.11.2026 10:23:00 CET | Press release
Robbyant, an embodied AI company within Ant Group, today announced the open-source release of LingBot-Touch, a tactile foundation model that gives robots a critical missing sense by enabling robust touch perception. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109284905/en/ LingBot-Touch encodes magnetic tactile, visual tactile, and piezoresistive signals into unified tactile tokens for use by different action models. Pre-trained on nearly 5,000 hours of real-world tactile data, the model covers three mainstream sensing modalities—magnetic tactile, visual tactile, and piezoresistive sensing—and translates their diverse signals into a unified tactile representation. This allows different dexterous hands and action models to share and reuse tactile understanding, enabling robots to not only “see clearer” and “think deeper,” but also “feel sharper” during fine manipulation tasks, such as turning pages, unscrewing bottle ca
Wise Selects Navan to Modernize Global Travel Program10.11.2026 10:00:00 CET | Press release
Global financial technology company plans to improve traveler choice, cost control and visibility Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Wise (Nasdaq:WSE, LSE:WISE), the global financial technology company building the best way to move and manage the world's money, has selected Navan to manage its business travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109603155/en/ Global financial technology company plans to improve traveler choice, cost control and visibility “Our teams travel across the world to work together and support our customers, so it's important that booking and managing travel is straightforward,” said Hanro Hennig, VP Global Real Estate, Workplace and Risk at Wise. “We're working with Navan to make that experience simpler, while giving us better visibility and control over travel costs.” Key anticipated benefits of the partnershi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom